| TTN altered in cohorts of …ALTERED_INderived39 of 39show fewer |
|---|
| → altered in cohorts of | Skin Basal Cell Carcinoma 112 / 126 cases (89 %) · ssm · bcc_unige_2016 | — | — | Skin Basal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cutaneous Melanoma 388 / 470 cases (83 %) · ssm · TCGA-SKCM · largest of 9 cohorts | — | — | Cutaneous Melanoma | 9 | Observed | gdc | graph → |
| → altered in cohorts of | Lung Squamous Cell Carcinoma 345 / 484 cases (71 %) · ssm · lusc_tcga_pan_can_atlas_2018 · largest of 6 cohorts | — | — | Lung Squamous Cell Carcinoma | 6 | Observed | cbioportal | graph → |
| → altered in cohorts of | Skin Squamous Cell Carcinoma 58 / 83 cases (70 %) · ssm · cscc_ucsf_2021 · largest of 3 cohorts | — | — | Skin Squamous Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Small Cell Carcinoma 77 / 120 cases (64 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Melanoma 92 / 144 cases (64 %) · ssm · mel_dfci_2019 · largest of 5 cohorts | — | — | Melanoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Non-Small Cell Carcinoma 682 / 1,144 cases (60 %) · ssm · nsclc_tcga_broad_2016 · largest of 3 cohorts | — | — | Lung Non-Small Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastroesophageal Junction Adenocarcinoma 276 / 518 cases (53 %) · ssm · stes_tcga_pub · largest of 3 cohorts | — | — | Gastroesophageal Junction Adenocarcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Carcinoma 297 / 559 cases (53 %) · ssm · TCGA-UCEC · largest of 5 cohorts | — | — | Endometrial Carcinoma | 5 | Observed | gdc | graph → |
| → altered in cohorts of | Esophageal Adenocarcinoma 97 / 185 cases (52 %) · ssm · esca_tcga · largest of 4 cohorts | — | — | Esophageal Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Adenocarcinoma 272 / 566 cases (48 %) · ssm · luad_tcga_pan_can_atlas_2018 · largest of 12 cohorts | — | — | Lung Adenocarcinoma | 12 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colon Adenocarcinoma 202 / 429 cases (47 %) · ssm · coad_tcga_gdc · largest of 4 cohorts | — | — | Colon Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastric Adenocarcinoma 217 / 478 cases (45 %) · ssm · stad_tcga · largest of 7 cohorts | — | — | Gastric Adenocarcinoma | 7 | Observed | cbioportal | graph → |
| → altered in cohorts of | Head and Neck Carcinoma, Other 46 / 108 cases (43 %) · ssm · ohnca_cptac_gdc | — | — | Head and Neck Carcinoma, Other | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Head and Neck Squamous Cell Carcinoma 211 / 515 cases (41 %) · ssm · hnsc_tcga_pan_can_atlas_2018 · largest of 5 cohorts | — | — | Head and Neck Squamous Cell Carcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Rectal Adenocarcinoma 61 / 155 cases (39 %) · ssm · read_tcga_gdc | — | — | Rectal Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Endometrioid Adenocarcinoma 89 / 247 cases (36 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Hepatocellular Carcinoma 177 / 494 cases (36 %) · ssm · hcc_clca_2024 · largest of 7 cohorts | — | — | Hepatocellular Carcinoma | 7 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Squamous Cell Carcinoma 49 / 139 cases (35 %) · ssm · escc_ucla_2014 · largest of 2 cohorts | — | — | Esophageal Squamous Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Bladder Urothelial Carcinoma 155 / 474 cases (33 %) · ssm · blca_msk_tcga_2020 · largest of 10 cohorts | — | — | Bladder Urothelial Carcinoma | 10 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cervical Squamous Cell Carcinoma 91 / 291 cases (31 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts | — | — | Cervical Squamous Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Ewing Sarcoma 30 / 107 cases (28 %) · ssm · es_dfarber_broad_2014 | — | — | Ewing Sarcoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colorectal Adenocarcinoma 278 / 1,015 cases (27 %) · ssm · crc_sysucc_2022 · largest of 8 cohorts | — | — | Colorectal Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| → altered in cohorts of | High-Grade Serous Ovarian Cancer 110 / 523 cases (21 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | High-Grade Serous Ovarian Cancer | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Ampulla of Vater Carcinoma 33 / 160 cases (21 %) · ssm · ampca_bcm_2016 | — | — | Ampulla of Vater Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Meningioma 23 / 115 cases (20 %) · ssm · mng_utoronto_2021 | — | — | Meningioma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Multiple Myeloma 181 / 961 cases (19 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Invasive Breast Carcinoma 187 / 1,066 cases (18 %) · ssm · brca_tcga_pan_can_atlas_2018 · largest of 13 cohorts | — | — | Invasive Breast Carcinoma | 13 | Observed | cbioportal | graph → |
| → altered in cohorts of | B-Cell Non-Hodgkin Lymphoma 52 / 297 cases (18 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Combined Hepatocellular Carcinoma and Cholangiocarcinoma 28 / 173 cases (16 %) · ssm · hccihch_pku_2019 | — | — | Combined Hepatocellular Carcinoma and Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Malignant Breast Neoplasm 28 / 174 cases (16 %) · ssm · CMI-MBC | — | — | Malignant Breast Neoplasm | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Clear Cell Renal Cell Carcinoma 71 / 451 cases (16 %) · ssm · kirc_tcga · largest of 5 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Prostate Adenocarcinoma 151 / 1,013 cases (15 %) · ssm · prad_p1000 · largest of 8 cohorts | — | — | Prostate Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| → altered in cohorts of | Pancreatic Adenocarcinoma 56 / 383 cases (15 %) · ssm · paad_qcmg_uq_2016 · largest of 5 cohorts | — | — | Pancreatic Adenocarcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Glioma 109 / 812 cases (13 %) · ssm · lgggbm_tcga_pub · largest of 12 cohorts | — | — | Diffuse Glioma | 12 | Observed | cbioportal | graph → |
| → altered in cohorts of | Renal Cell Carcinoma 44 / 352 cases (13 %) · ssm · rcc_cptac_gdc · largest of 2 cohorts | — | — | Renal Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Papillary Renal Cell Carcinoma 35 / 282 cases (12 %) · ssm · kirp_tcga · largest of 3 cohorts | — | — | Papillary Renal Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Small Lymphocytic Lymphoma 76 / 1,075 cases (7.1 %) · ssm · cll_broad_2022 | — | — | Small Lymphocytic Lymphoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Acute Lymphoblastic Leukemia 54 / 768 cases (7.0 %) · ssm · TARGET-ALL-P2 | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | gdc | graph → |